You can find out more about NPF's National Medical Director, Dr. Michael S. Okun, by also visiting the NPF Center of Excellence, University of Florida Center for Movement Disorders & Neurorestoration.
One of the most common questions we receive on the “Ask the Doctor NPF forum” is how best to address constipation. In patients with Parkinson’s disease, this symptom is both common and disabling. Because of this, there is a critical need for newer and better treatment approaches. In this month’s What’s Hot in PD column, I will review a new drug treatment for constipation and summarize other helpful tips for relieving the condition.
In the May 22, 2012 issue of the journal Neurology, William Ondo, M.D., and colleagues evaluated the efficacy and tolerability of the drug lubiprostone (Amitiza) as a treatment for constipation. In a double-blind, randomized and controlled study, 52 Parkinson’s patients received lubiprostone or placebo (inactive substance) for two weeks and were subsequently followed for four weeks.
Lubiprostone acts by turning on chloride channels in the mucosa of the gastrointestinal tract. It enhances fluid secretion, and improves the overall digestive movement of the stomach and intestines. Furthermore, it does not affect blood electrolytes such as sodium and potassium, making it a very safe treatment.
The study results revealed a “marked or very marked clinical global improvement in 16 of 25 (64%) subjects receiving drug versus 5 of 27 (18.5%) receiving placebo.” Constipation rating scales and stool diaries improved. The adverse event profile was excellent, and loose stools were the most common individual patient complaint.
Under recognized and under treated, constipation is often not addressed even though it affects the majority of Parkinson’s disease sufferers. In the original 1817 essay (An Essay on the Shaking Palsy) describing Parkinson’s disease, constipation was included as an important patient issue, and, unfortunately, almost 200 years later patients still suffer with this problem.
We now know that, in Parkinson’s patients, it takes the stomach longer to empty, and it also takes longer for food to move through the intestines. Muscles and nerves within the gastrointestinal tract are affected by the degenerative process, and interestingly, abnormal protein deposits called Lewy bodies have been discovered in the intestines. Lewy bodies also are found in the brains of Parkinson’s patients, and their presence in the intestines leads us to believe that constipation is likely a core symptom of Parkinson’s disease.
Lubiprostone is a promising advance in the care of Parkinson’s patients. Though it may not work for every sufferer, it should be considered as an option. We recommend that patients employ a comprehensive plan to address constipation. Over the years we have found that the use of many practical therapies (see below), often in combination, to be extremely helpful. Future studies of lubiprostone will need to be longer than four weeks, and should include more information about the type of Parkinson’s patient that most likely will benefit.
Common treatment approaches for constipation in Parkinson’s disease have included:
- Optimization of Parkinson drugs
- Polyethylene glycol
- Fiber supplements
- 6-8 glasses of plain water a day
- Vigorous daily exercise
- Stool softeners
More detailed information on the treatment of Parkinson’s disease constipation is available from two NPF Centers of Excellence.
Posted: 6/4/2012 7:38:25 AM by
Browse current and archived What's Hot in PD? articles, the National Parkinson Foundation's monthly blog for people with Parkinson's written by our National Medical Director, Dr. Michael S. Okun.
IPX066 and What Patients Really Want in New Carbidopa/Levodopa (Sinemet) Formulations
The Weather Forecast for Parkinson’s Disease Calls for Worldwide Economic Storm
Defeating the Barriers to Implementing Exercise Regimens in Parkinson’s Disease Patients
When should you start medication therapy for Parkinson’s disease?
Neurologist Care Reduces Hospitalizations in Parkinson's Disease
A Victory in Court for Parkinson's Disease Patients who Require Ongoing Rehabilitative Therapies
Given the recent FDA announcement about Mirapex (pramipexole), should I be worried about dopamine agonists?
What about the new Parkinson’s Disease Vaccine? What should I know?
Caffeine as a Potential Treatment for Parkinson’s Disease
Time to Consider GPi DBS for Parkinson’s Disease: A Shift in the Practice of Patient Selection for DBS
A New Treatment for Parkinson’s Disease-Related Constipation
Too Many Pills: Improving Delivery Systems for Parkinson’s Disease Drugs
Measuring Quality and Assessing Depression in Parkinson's Disease
Watch out for Unexpected Obstacles if You Use a Cueing Strategy to Break Freezing of Gait in Parkinson’s Disease
Pill Color, Generic Medications and Insurance Issues: Important Medication-Related Tips for the Parkinson’s Disease Patient
Are Blood Tests for Parkinson’s Disease on the Horizon?
Placing Stem Cells in Animal Models of Parkinson’s Disease: Another Important Step
Important News for the Parkinson’s Disease Community: More Evidence that Sinemet and Madopar are Not Toxic and do Not Accelerate Disease Progression
The Case for All Parkinson’s Disease Patients to be Co-managed by a Primary Care-Neurologist Team
Scientists say Research on Brain Proteins Involved in Parkinson’s Disease is “Shaping” Up
Who Actually Takes Care of Most of the Parkinson’s Patients Worldwide: The Need for Education and the Parkinson’s Toolkit
If you are Dizzy or Passing Out, it could be Your Parkinson’s Disease or Parkinson’s Disease Medications
How Will Group Visits for Parkinson’s Disease Fit into the Future of Parkinson’s Disease Care?
Why Patients Should be Wary of Chelation Therapy for Parkinson’s Disease
Opening the Door to Gene Therapy in Parkinson’s Disease: The Need for Refinement of the Technology and Approach
Does it Matter if I Can’t Get Brand Sinemet?
Should I get a DaTscan or PET scan to confirm my diagnosis of Parkinson’s disease?
A Critical Reappraisal of the Worst Drugs in Parkinson’s Disease
Environmental Risks for PD: Manganese, Welding, Mining, and Parkinsonism
Calling for the FDA to Revise the Eight Sinemet a Day Rule
Dry Cleaning Solvents and Potential Environmental Risks for Developing Parkinson’s Disease
Maintaining the Balance: Why Parkinson’s Disease Patients Need to Understand Drug Recalls, Withdrawals, and Safety Alerts
Shining a Light on Parkinson’s Disease: Optogenetics Has a Bright Future in Research
Poor Medication Management of Parkinson's Disease During Hospital Admissions: Patients and Families Can Improve Their Hospital-Based Management
Why Are Patches and Continuous Release Technology a Big Deal to Parkinson's?
Is the PD SURG Trial Another Surge Forward for DBS Therapy?
Cycling in PD in Those Who Can’t Walk: Is it Possible?
New iPS Stem Cells for PD: What Does it Mean?
Time for Comprehensive Care Networks for PD
Is Parkinson's Disease a Prion Disease?
Parkinson's Disease Linked to Gaucher's Disease
Brain Cells Keep Time Stamps: Implications for Parkinson's Disease Therapies
Is it Safe to Have an MRI with a DBS in Place?
Take Care of Your Bones as They Are Affected in Parkinson's Disease (Even in Men)
Is it Time to Start Paying Attention to Pain Symptoms in Parkinson's Disease Patients?
Glutathione Fails to Demonstrate Significant Improvement in PD Symptoms
Keeping an Eye on Trials Important to the Parkinson's Disease Patient
Increased Risk of Melanoma in Parkinson's Disease
Finally a DBS Expert Consensus Statement Aimed at Their True Customers: The Patients
Pesticides and Environmental Exposure in Parkinson's disease: Should We Stay Away From the Stink Truck?
Is Exercise Effective Treatment and Protection Against PD?
Why are Transplant Trials Struggling to Succeed in the Treatment of PD?
Are Monoamine Oxidase Inhibitors Disease Modifying or Neuroprotective in PD?
Update on Gene Therapy for Parkinson's Disease